Vivos Therapeutics (VVOS) executive compensation, 2025 proxy

R. Kirk Huntsman, Chief Executive Officer, was paid $1.3M in 2024, up 130% from $567,794 the year before.

Filed
September 29, 2025
Annual meeting
November 4, 2025
Pay year
2024
Named executives
2
CEO total pay
$1.3M+130% vs prior year
CEO 2024 option awards
$801,578Black-Scholes grant-date valuation
CFO 2024 total pay
$705,919
2025 CEO base salary
$450,000Effective January 1, 2025
2025 CFO base salary
$320,000Effective January 1, 2025
CEO target cash incentive
75%Of base salary
CFO target cash incentive
50%Of base salary

How Huntsman was paid

$1.3M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary31%Option awards61%Non-equity incentive6%All other compensation1%

Named executive officers

ExecutiveTotal
R. Kirk HuntsmanChief Executive Officer$1,306,906
Bradford AmmanChief Financial Officer$705,919

What changed and why

  • $1.3M$1,306,906 was CEO total compensation in 2024, compared with $567,794 in 2023.
  • $802K$801,578 was the CEO’s 2024 option-award value, based on a Black-Scholes valuation.
  • $706K$705,919 was CFO Bradford Amman’s total compensation in 2024.
  • $450K$450,000 and $320,000 are the CEO and CFO base salaries under agreements effective January 1, 2025.
  • 75%75% and 50% are the CEO and CFO target annual cash incentive percentages, respectively.
  • Performance-based options vest based on revenue growth, total shareholder return, and positive cash flow metrics.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.